Menu
image description

Category: Therapeutics

10 Lupus Therapeutics Studies Currently Underway

  TAK-079 A Study to Evaluate the Safety of TAK-079 PAISLEY-SLE A Phase II study to evaluate a novel, oral therapy in SLE ORKIDS A study to evaluate the effects of krill oil in SLE LOTUS A Phase III study to evaluate Stelara® in SLE DIVINE A study to evaluate a novel imaging procedure to […] Read More

Two Lupus Therapeutics Studies Report Positive Results at 2019 ACR/ARP Annual Meeting

November 12, 2019 Two positive clinical studies presented at the 2019 ACR/ARP Annual Meeting were conducted through the Lupus Clinical Investigators Network (LuCIN) formed and managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance. Results of both studies hold promise to improve how physicians can better monitor lupus patients’ symptoms and disease activity. […] Read More

Welcoming Daniel J. Wallace, MD to Lupus Therapeutics

The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate […] Read More

Lupus Therapeutics Shifting the Paradigm

The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affiliated organization) and since the program started in 2017, […] Read More

PALS Clinical Trial Program Opens at Five Universities

August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […] Read More

Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.  Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] Read More

Taking Scientific Discovery: From Lab Bench to You

April, 2019 Making new and efficacious lupus therapies available to patients has long been a major focus of the Lupus Research Alliance, and today we’ve taken an important step toward that aim. Based on a breakthrough discovery made by Betty Diamond, MD of Feinstein Institutes for Medical Research, Meggan Mackay, MD, MS, also at Feinstein, will […] Read More

A Promising New Therapy

April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players  to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] Read More